Vyant Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Warrants

Warrants

6 Months Ended

Jun. 30, 2019

On January 14, 2019, we issued 933,334 warrants to purchase common stock at $0.2475 per share. The warrants are immediately exercisable and expire on January 9, 2024. On January 31, 2019 we issued 1,065,217 warrants to purchase common stock at $0.253 per share. These warrants are immediately exercisable and expire on January 26, 2024. All of these warrants were issued in conjunction with the 2019 Offerings.

During the three and six months ended June 30, 2019, 3,675,000 warrants issued as part of the 2017 Offering expired unexercised.

The following table summarizes the warrant activity for the six months ended June 30, 2019 (in thousands, except exercise price):



Issued With / For	Exercise Price			Warrants Outstanding January 1, 2019	2019 Warrants Issued	2019 Warrants Expired		Warrants Outstanding June 30, 2019
Non-Derivative Warrants:
Financing	$	10.00		243	—	—		243
Financing	15.00			276	—	—		276
2015 Offering	5.00			3,450	—	—		3,450
2017 Debt	0.92			443	—	—		443
2019 Offering	0.2475			—	933	—		933
2019 Offering	0.253			—	1,065	—		1,065
Total non-derivative warrants	3.86		B	4,412	1,998	—		6,410
Derivative Warrants:
2016 Offerings	2.25		A	1,968	—	—		1,968
2017 Offering	2.35		A	3,500	—	(3,500	)	—
2017 Offering	2.50		A	175	—	(175	)	—
Total derivative warrants	2.25		B	5,643	—	(3,675	)	1,968
Total	$	3.48	B	10,055	1,998	(3,675	)	8,378


A	These warrants are subject to fair value accounting and contain a contingent net cash settlement feature. See Note 12.


B	Weighted-average exercise prices are as of June 30, 2019.